Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Ends Marketing Collaboration With Mochida On Diovan

This article was originally published in PharmAsia News

Executive Summary

Swiss drugmaker Novartis announced the company will end a joint marketing agreement with Mochida Pharmaceutical on hypertension drug Diovan (valsartan) by the end of December. Novartis will be solely marketing the drug in Japan starting next year. Novartis is viewed to have accomplished its original goal of expanding Diovan's Japanese market shares with the help of Mochida. The two companies developed the relationship in February 2007. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC069981

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel